おはようございます！ #少女夢幻論大全 2日目よろしくお願いします🙇 雨です！気をつけてお越しください☔️ ...
個人勢VTokre⌇ᴠᴀʟᴏʀᴀɴᴛ⌇麻雀一番街⌇ʟɪᴠᴇ𝟤ᴅ作成中⌇ꜰᴍ-›⛓️🛜⌇ꜰᴀ #篭守の落書き帳⌇ https://t.co ...
ELAHERE (mirvetuximab soravtansine) is the first and only antibody-drug conjugate (ADC) approved in Japan for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant recurrent ...
In this report from WCLC 2026, overall survival outcomes from the phase 3 PAPILLION study are provided. The median overall survival was 34.3 months with amivantamab-chemotherapy and 27.9 months with ...
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Last week, President Jennifer Cowley delivered her final State of the University address, reflecting on UT Arlington's extraordinary momentum and bright future. On behalf of the UT System Board of ...
→ As Takeda celebrates a pair of FDA approvals, one of its top execs will be retiring in June 2027. “It has been the privilege of a lifetime to lead Takeda’s R&D organization and work ...
Retirement of Takeda's R&D chief and a Daiichi Sankyo legal win made our news this week. (sankai/iStoc /Getty Images Plus) Takeda's long-time R&D chief Andy Plump will retire. Daiichi Sankyo beat back ...
Students, faculty, staff and stakeholders gathered for UTA President Jennifer Cowley’s annual State of the University address Thursday at Texas Hall. Cowley provided updates to the university on ...
Christophe Weber, a university trustee and Husky parent, was the guest in the 2026-2027 academic year’s first Presidential Leadership Series event. Christophe Weber, former CEO and president of Takeda ...
A few months after a new CEO stepped up to helm Takeda, the drugmaker will now have to prepare for another leadership change as its long-time R&D head plans his exit. Takeda’s R&D chief Andy Plump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results